Thursday , October 19 2017
Home / Letter From The Editor / Editor’s Note, SGLT-2 Inhibitors June Special Edition

Editor’s Note, SGLT-2 Inhibitors June Special Edition

There was a lot of activity at the ADA this year and considerable attention was focused on the SGLT2 inhibitors. This class of drugs, which includes the currently approved canagliflozin and dapagliflozin and the hopefully-soon-to-be-approved empagliflozin as well as about 20 others, has been getting a lot of attention because of their ability to lower A1c, improve blood pressure, and reduce weight. This month we have some of the best information from the ADA for you to review so you can make your own intelligent decisions as to why and when to add these medications to your patients’ therapy.